Intralesional Antigen Immunotherapy in the Treatment of Periungual Warts.
Candida antigen
MMR
PPD
intralesional antigen immunotherapy
periungual warts
Journal
Journal of cutaneous medicine and surgery
ISSN: 1615-7109
Titre abrégé: J Cutan Med Surg
Pays: United States
ID NLM: 9614685
Informations de publication
Date de publication:
Historique:
pubmed:
29
1
2021
medline:
23
11
2021
entrez:
28
1
2021
Statut:
ppublish
Résumé
Intralesional immunotherapy using different types of antigens is considered an effective and safe treatment option for different types of warts. However, there are few studies that illustrate the use of these antigens in the treatment of periungual warts as a distinct type of warts. To evaluate the efficacy and safety of three antigens: measles, mumps, rubella (MMR) vaccine, Candida antigen, and purified protein derivative (PPD) in the treatment of periungual warts. The study included 150 patients who were randomly assigned to 3 groups with 50 patients in each. Each agent was injected intralesionally at a dose of 0.1 mL into the largest wart at 2-week intervals until complete clearance or for a maximum of 5 sessions. Complete clearance of warts was observed in 70%, 80%, and 74% in PPD, Candida antigen, and MMR vaccine groups, respectively. There was no statistically significant difference regarding the therapeutic response between the 3 studied groups. Adverse effects were transient and insignificant in the 3 groups. No recurrence of the lesions was reported in any of the studied groups. Intralesional antigen immunotherapy seems to be an effective therapeutic option for the treatment of periungual warts.
Sections du résumé
BACKGROUND
BACKGROUND
Intralesional immunotherapy using different types of antigens is considered an effective and safe treatment option for different types of warts. However, there are few studies that illustrate the use of these antigens in the treatment of periungual warts as a distinct type of warts.
OBJECTIVE
OBJECTIVE
To evaluate the efficacy and safety of three antigens: measles, mumps, rubella (MMR) vaccine, Candida antigen, and purified protein derivative (PPD) in the treatment of periungual warts.
METHODS
METHODS
The study included 150 patients who were randomly assigned to 3 groups with 50 patients in each. Each agent was injected intralesionally at a dose of 0.1 mL into the largest wart at 2-week intervals until complete clearance or for a maximum of 5 sessions.
RESULTS
RESULTS
Complete clearance of warts was observed in 70%, 80%, and 74% in PPD, Candida antigen, and MMR vaccine groups, respectively. There was no statistically significant difference regarding the therapeutic response between the 3 studied groups. Adverse effects were transient and insignificant in the 3 groups. No recurrence of the lesions was reported in any of the studied groups.
CONCLUSIONS
CONCLUSIONS
Intralesional antigen immunotherapy seems to be an effective therapeutic option for the treatment of periungual warts.
Identifiants
pubmed: 33504211
doi: 10.1177/1203475420988859
doi:
Substances chimiques
Antigens, Fungal
0
Measles-Mumps-Rubella Vaccine
0
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM